Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Official Title

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Summary:

This is a prospective study investigating the disease course of patients with colorectal cancer that have had their cancer spread to their liver. The aim of this study is find potential biomarkers for disease recurrence and therapeutic targets for prognostic information.

Trial Description

Primary Outcome:

  • Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumour recurrence in clinical environments
Secondary Outcome:
  • Identification of epigenetic profiles of recurring tumour clones through serial DNA characterization on the NGS platform
  • Identification of epigenetic profiles of recurring tumour clones through serial RNA characterization on the NGS platform
  • Identification of DNA methylation profiles of recurring tumour clones through serial methylome analysis via MethylSeq
  • Non-invasive detection of cfDNA methylation profiles by performing ultra-deep targeted NGS on blood samples
  • Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples
Colorectal cancer (CRC), the 2nd leading cause of cancer mortality, often has a pattern of targeting the liver during initial metastases. The Comprehensive Genomic Profiling of Colorectal Cancer Patients with Isolated Liver Metastases to Understand Response and Resistance to Cancer Therapy (COMPARISON) study aims to assess the disease course of CRC by collecting primary tumour and metastatic liver specimens following pre-operative chemotherapy. If relapse occurs following surgical resection of the liver, biopsies will also be done for molecular analysis. As a result, these samples can be analyzed for chemotherapy resistance mechanisms and therapeutic targets to determine potential clinical outcomes for this particular subset of CRC patients.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society